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Abstract: Long-term perfusion of liver grafts outside of the body may enable repair of poor-quality livers
that are currently declined for transplantation, mitigating the global shortage of donor livers. In current
ex vivo liver perfusion protocols, hyperoxic blood (arterial blood) is commonly delivered in the portal
vein (PV). We perfused porcine livers for one week and investigated the effect of and mechanisms behind
hyperoxia in the PV on hepatic arterial resistance. Applying PV hyperoxia in porcine livers (n = 5,
arterial PV group), we observed an increased need for vasodilator Nitroprussiat (285 ± 162 ml/week)
to maintain the reference hepatic artery flow of 0.25 l/min during ex vivo perfusion. With physiologic
oxygenation (venous blood) in the PV the need for vasodilator could be reduced to 41 ± 34 ml/week
(p = 0.011; n = 5, venous PV group). This phenomenon has not been reported previously, owing to
the fact that such experiments are not feasible practically in vivo. We investigated the mechanism of
the variation in HA resistance in response to blood oxygen saturation with a focus on the release of
vasoactive substances, such as Endothelin 1 (ET-1) and nitric oxide (NO), at the protein and mRNA
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Hyperoxia in portal vein causes 
enhanced vasoconstriction 
in arterial vascular bed
Dilmurodjon Eshmuminov1,7, Dustin Becker2,7, Max L. Hefti3,7, Matteo Mueller1, 
Catherine Hagedorn1, Philipp Dutkowski1, Philipp Rudolf von Rohr2, Maximilian Halbe4, 
Stephan Segerer5, Mark W. Tibbitt6, Lucia Bautista Borrego1,7, Martin J. Schuler3,7* & 
Pierre‑Alain Clavien1,7
Long‑term perfusion of liver grafts outside of the body may enable repair of poor‑quality livers that are 
currently declined for transplantation, mitigating the global shortage of donor livers. In current ex vivo 
liver perfusion protocols, hyperoxic blood (arterial blood) is commonly delivered in the portal vein 
(PV). We perfused porcine livers for one week and investigated the effect of and mechanisms behind 
hyperoxia in the PV on hepatic arterial resistance. Applying PV hyperoxia in porcine livers (n = 5, 
arterial PV group), we observed an increased need for vasodilator Nitroprussiat (285 ± 162 ml/week) 
to maintain the reference hepatic artery flow of 0.25 l/min during ex vivo perfusion. With physiologic 
oxygenation (venous blood) in the PV the need for vasodilator could be reduced to 41 ± 34 ml/week 
(p = 0.011; n = 5, venous PV group). This phenomenon has not been reported previously, owing to 
the fact that such experiments are not feasible practically in vivo. We investigated the mechanism of 
the variation in HA resistance in response to blood oxygen saturation with a focus on the release 
of vasoactive substances, such as Endothelin 1 (ET‑1) and nitric oxide (NO), at the protein and mRNA 
levels. However, no difference was found between groups for ET‑1 and NO release. We propose direct 
oxygen sensing of endothelial cells and/or increased NO break down rate with hyperoxia as possible 
explanations for enhanced HA resistance.
The unprecedented success of liver transplantation over the past three decades has restored normal function 
to many patients suffering from acute and end-stage liver failure. However, the proliferation of life-changing 
transplantation has resulted in a worldwide shortage of available liver  grafts1,2. Thus, strategies to expand the 
pool of suitable organs for transplantation is a major focus of clinical  research2,3. Ex vivo machine perfusion has 
emerged as a leading technology to increase the available donor pool, as this approach can rescue injured grafts, 
initially not suitable for transplantation, and concomitantly predict post-transplant graft  function4–6.
The liver is a highly perfused organ, receiving 25% of the cardiac output while comprising only 2.5% of the 
body  weight7. The liver possesses a dual blood supply from the portal vein (PV) and the hepatic artery (HA) 
as well as a unique microcirculation that mixes the arterial blood (high oxygen saturation) from the HA with 
the venous blood (partial oxygen saturation) from the PV. However, a recent systematic review of ex vivo liver 
perfusion protocols demonstrated that non-physiologic arterial blood delivery to the PV is common in both 
the clinical and experimental  settings8,9. It is necessary to supply sufficient oxygen in order to maintain viability 
of the metabolically active liver; however, the value of preventing excessive oxygen is not as intuitive despite 
the fact that excessive oxygenation could be deleterious in the clinical  setting10,11. Further, the specific effect of 
delivering arterial blood to the PV on liver hemodynamics has not been explored, owing to the fact that such 
experiments are difficult to perform in vivo.
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Our multidisciplinary team, consisting of surgeons, biologists, and engineers, recently introduced a liver 
perfusion technology that enables preservation of injured human livers for up to one  week5. The technology 
serves as an “artificial body” that recapitulates core bodily functions to maintain liver viability ex vivo. The initial 
machine setup was based on the state of the  art8, and additional functionality was introduced to the perfusion 
machine sequentially. The biological relevance of each unit operation was demonstrated using porcine  livers5. 
Based on current machine perfusion protocols, we supplied the PV with arterial oxygen content (oxygen satura-
tion: 95–100%) during our initial  experiments8,9. However, the blood supply of the PV in vivo is at venous oxygen 
saturation (< 80%) and we hypothesized that mimicking this oxygen saturation would improve liver function 
during machine perfusion. Therefore, we modified our perfusion protocol to supply the PV with venous blood. 
Surprisingly, we observed significant variation in the HA resistance depending on oxygen content in the  PV5. 
In this study, we related the observed hemodynamic differences in the HA in a porcine model to the release of 
vasoactive substances. Our findings suggest that direct oxygen sensing of endothelial cells and/or increased NO 
break down rate with hyperoxia may cause enhanced HA resistance.
Materials and methods
Perfusion machine. The engineered liver perfusion machine includes one pump operating  in pulsa-
tile mode, an automated dialysis unit, an “artificial pancreas” based on feedback controlled insulin infusions 
depending on real time glucose measurements in blood, tight automated hemodynamic control, diaphragm 
simulation, and one oxygenator with controlled gas mixture supply (N2,  O2,  CO2) to maintain physiologic blood 
gas parameters (Fig. 1). For a detailed description of the development process of the perfusion machine and the 
applied perfusion protocol, we refer to our previous  work5. Amino acids (for nutrition), antibiotics, bile acids, 
and steroids were provided continuously by means of direct infusion to the blood  supply5. Blood gas parameters 
including  pO2 (partial pressure  O2),  pCO2 (partial pressure  CO2), and pH were measured in the HA and PV by 
online blood gas sensors (Terumo, CDI 500). Based on the current levels of  pO2 (target 10–12 kPa) and pH in 
the HA, an automated algorithm defined the individual required gas flow rates of  O2,  N2, and  CO2 supplied to 
the oxygenator. The system continuously measured the oxygen saturation in the vena cava  (vSO2) by the Terumo, 
CDI 500 device.
Oxygen content and consumption. Oxygen content (1), delivery (2), and consumption (3) were calcu-
lated by the following equations:
1. Oxygen content (C*O2)  (mlO2/dL) = (1.34 × hemoglobin concentration (g/dL)  × SO2(%)/100%) + (0.0031 × 
PO2 (mmHg))
  * signifies the location of measurement (HA, PV, or VC). Note, online VC oxygen content was calculated 
without the  pO2 value in the VC line.
2. Oxygen delivery  (DO2)  (mlO2/min) = (HA flow(ml/min)xC
aO2) + (PV flow(ml/min)xC
pvO2)
3. Oxygen consumption(VO2)  (mlO2/min) = DO2-(HA + PV flow(ml/min))xC
vcO2
Porcine livers and experimental groups. Livers were procured respecting local animal protection regu-
lation.
Livers and blood were procured under general anesthesia in a standardised  manner5. The animal study proto-
col was approved by veterinarian office of Canton Zurich (registration number: 26538-ZH079/15). All methods 
were in accordance with relevant guidelines and regulations. During surgery, in vivo flow in the HA and PV 
was measured with VeriQ (Medistim). After back table preparation, the livers were connected to the perfusion 
machine primed with autologous leukocyte depleted blood at 34 °C. The targeted perfusion duration was one 
week. This target was based on the ability of human organs to regenerate in vivo within this time  period12,13.
The following experimental groups were designed:
• Group 0 “Initial” (n = 4): Initial experiments were performed providing arterial blood in the PV without HA 
hemodynamic control. For arterial oxygen content in the PV, blood flow after the oxygenator is split into 
two lines: one for the PV line and the second for the HA line (Fig. 1 a). Consequently, the HA and PV had 
similar blood gas parameters. A pinch valve controlled the flow in the PV to 1 l/min. vSO2 in the VC line 
was recorded but not used for controlling any parameters. The HA pressure was maintained at mean arterial 
pressure (MAP) > 65 mmHg. In vivo, PV flow is not controlled by the liver and depends on intestinal blood 
flow  regulation7. Thus, the PV was provided with a fixed flow rate of 1 l/min.
• Group 1 “Arterial PV” (n = 5): Arterial oxygen content was delivered in the PV as for Group 0 and the HA 
resistance was controlled tightly. The minimal HA flow rate was defined as 0.25 l/min. If the flow rate reduced 
to less than 0.25 l/min, the system injected the vasodilator Nitroprussiat (Nitropussiat Fides, Rottapharm, 
1 mg/ml) in an automated manner. Note, the reference flow parameters in the HA (0.25 l/min) and PV (1 l/
min) were based on in vivo flow measurement with VeriQ (Medistim) during liver procurement.
• Group 2 “Venous PV” (n = 5): Physiologic venous oxygen content was delivered in the PV. To achieve the 
desired oxygen saturation levels, blood from the reservoir (oxygen saturation ~ 65%) was mixed with a por-
tion of arterial blood from the oxygenator (Fig. 1 b). The control algorithm adjusted the mixing fractions 
such that the VC oxygen saturation  (vSO2), which was monitored continuously, remained at 65%. For this 
purpose, the system controlled the bypass flow rate from the oxygenator and reservoir individually, while 
maintaining a total blood flow rate of 1 l/min5. Similar to Group 1 (Arterial PV), HA resistance was controlled 
by infusions of Nitroprussiat.
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Measurements and analytics. Liver function was evaluated with adenosine triphosphate (ATP) produc-
tion in tissue, bile flow, blood urea nitrogen, and lactate clearance. The following injury markers were evaluated 
in the perfusate: aspartate aminotransferase (AST). Cytochrome C for mitochondrial injury, 8-hydroxy-2-deoxy 
guanosine for DNA damage in perfusate. The mRNA expression of cytokines (IL-6, IL-10), ICAM-I (Inter-
cellular Adhesion Molecule-1) for endothelial cells, and TLR4 for Kupffer cells were measured. Histology was 
performed with haematoxylin–eosin (H&E) staining for necrosis and von Willebrand factor (vWF) staining for 
endothelial  activation14.
Statistics. Matlab R2017a (MathWorks, USA) was used for statistical analysis and graphs. Data was reported 
as mean with standard deviation (s.d.) with p value < 0.05 as significant. Two-tailed Student’s t-test was used to 
compare study groups.
Results
Tight hemodynamic control was necessary to reach one week perfusion. Long-term liver per-
fusion was prevented by hemodilution and disturbed perfusate quality, including toxic uraemia (blood urea 
nitrogen > 100 mmol/l) and hypernatremia (sodium level > 200 mmol/l) in the absence of an integrated dialysis 
 unit5. Thus, we integrated a dialysis unit to improve our protocol and machine development (Group 0). However, 
Figure 1.  Schematic illustration of the perfusion loops for arterial PV (a) and venous PV groups (b). (a) In 
arterial PV group, arterial blood was provided in the PV with total PV flow rate of 1 l/min. For this purpose 
blood flow was split after the oxygenator into the PV and HA lines with the same oxygen content. (b) In venous 
PV group, venous blood was provided in the PV with total PV flow rate of 1 l/min. For this purpose, oxygen 
deprived blood from the liver output was mixed with oxygenated blood after oxygenator. Flow rates in the 
arterial and deoxygenated lines were automatically adjusted to maintain an oxygen saturation at the liver output/
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integration of dialysis alone was not sufficient to perfuse livers in a viable state for one week during initial experi-
ments (Group 0). Specifically, while supplying the PV with arterial blood and applying dialysis, we observed 
increased HA resistance during perfusion, where the resistance increased compared with in vivo values (Fig. 2a). 
Livers stopped producing bile on perfusion day 3–6; the PV resistance increased at a similar time point (Fig. 2b). 
We terminated the experiments in this group prematurely on account of the cessation of bile flow cessation and 
portal hypertension (> 30 mmHg).
Arterial oxygen saturation in the PV was associated with increased HA resistance. The 
observed increase in HA resistance was an intriguing finding. We hypothesized that control of HA resistance 
should enable long-term perfusion of viable livers. Therefore, we developed an automated algorithm to regu-
late HA resistance through the controlled supplementation of a vasodilator (Nitroprussiat). We suspected that 
hyperoxia contributed to the elevated arterial resistance, based on previous reports in experimental setting and 
 humans15–18. In our protocol with arterial blood supplied to the PV (Group 1), high oxygen  (DO2) was delivered 
to the liver through the PV (Fig. 2c). We observed  vSO2 in liver output exceeding 80% and even reaching a level 
of close to 90% in some cases (Fig. 2d). To reduce the oxygen delivery to the liver  (DO2), the PV was supplied 
with physiologic venous blood (Group 2; Fig. 1 b). To ensure sufficient oxygenation of the liver, the oxygen 
saturation in the vena cava  (vSO2) was maintained at 65% based on current  recommendations
19. With venous 
oxygen content supplied to the PV (Group 2), significantly lower oxygen  (DO2) was delivered to the liver com-
pared with the same experiment using arterial blood in the PV (Group 1; Fig. 2c). Oxygen consumption  (VO2) 
was not different between the two groups (Fig. 2e). The increased  DO2 with arterial blood in the PV and no 
difference in  VO2 resulted in increased  vSO2 for Group 1 (arterial PV) as compared with Group 2 (venous PV; 
Fig. 2d). HA resistance was reduced with the supply of physiologic venous blood to the PV, as evidenced by the 
reduced demand for vasodilator at the same flow rate (Fig. 2f). The consumption of Nitroprussiat was reduced 
from 285 ± 162 ml/week in Group 1 to 41 ± 34 ml/week in Group 2 (p = 0.011), preventing hyperoxia mitigated 
HA resistance and enabling extended liver perfusion.
What is the mechanism behind enhanced arterial vasoconstriction with arterial blood in 
PV? To explore the underlying mechanism for the increased HA resistance with arterial blood in the PV, we 
investigated markers of vasoconstriction and vasodilation in the perfused livers. Specifically, we quantified the 
expression of Endothelin 1 (ET-1), a vasoconstrictor, and NO activity, a vasodilator. We observed no difference 
in ET-1 expression at the mRNA and protein levels between the two groups (Fig. 2g,h). To investigate if HA 
resistance was related to NO, we quantified NO activity in perfused livers from Groups 1 and 2. We observed no 
difference in the mRNA expression of endothelial nitric oxide synthase (eNOS) and inducible nitric oxide syn-
thase (iNOS; Fig. 2i,j). Similarly, the concentration of NO in the perfusate did not differ between the two groups 
(Fig. 2k). However, the measured NO concentration in the perfusate of livers from both groups was lower than 
in vivo values. Note, the concentration measured in vivo corresponded to whole body levels, whereas only the 
liver was producing NO ex vivo, which might explain the lower NO concentration during perfusion. Moreover, 
NO was partially washed out by the dialysis unit. Further, we investigated the effect of NO on heme oxygenase 1 
(HO1); HO1 mRNA expression was not different between the two groups, implying similar NO content in tissue 
(Fig. 2l). Since oxygen content was different in the tissue between groups with possible difference in superoxide 
levels, superoxide dismutase was measured. We did not find any difference at the mRNA and protein levels in 
superoxide dismutase between groups (Fig. 2 m, n).
Venous blood delivery in the PV is safe and sufficient for 1 week liver perfusion. To investigate 
the safety and efficacy of delivering venous blood in the PV, we analysed common injury parameters in both the 
perfusate and tissue as well as key liver functions. In the perfusate, we quantified aspartate aminotransferase 
(AST) as a marker of hepatocyte injury, Cytochrome C as a marker of mitochondrial injury, and 8-hydroxy-2′-
deoxyguanosine (8-OHdG) as a marker of DNA damage. We observed no difference in AST, Cytochrome C, and 
8-OhdG levels between the two groups (Fig. 3a–c). Next, we studied markers of tissue damage in the perfused 
liver tissue in each group. No difference was observed in mRNA expression of Toll-like Receptor 4 (TLR4), a 
marker of macrophage activation (Fig. 3d). Endothelial cells exhibited normal function based on Intracellular 
Adhesion Molecule 1 (ICAM-1) mRNA expression (Fig. 3e).
In addition, both groups demonstrated preserved liver structure based on histology with H&E staining, 
showing no relevant cell death and without caspase-3+cells (Fig. 3f,g). The livers also preserved glycogen in PAS 
staining, an indicator of liver health (Fig. 3h). Immunohistochemical staining of von Willebrand factor con-
firmed the observation of normal ICAM-1 expression (Fig. 3i). All livers in both groups, demonstrated normal 
liver function during sustained perfusion without any difference between groups. Livers produced bile (Fig. 3j), 
cleared lactate (Fig. 3k) and maintained albumin production (Fig. 3l). In total, these findings demonstrate that 
perfusion with venous blood in the PV is safe and sufficient during maching perfusion for one week.
Discussion
This work explored the change in HA resistance depending on the oxygen content in the PV during ex vivo perfu-
sion of porcine livers. The main findings of the study were, first, that arterial oxygen content in the PV delivers 
excessive oxygen to the liver. Second, hyperoxia causes HA vasoconstriction and prevents long-term perfusion. 
Third, the mechanism behind increased HA resistance with hyperoxia remains unclear. However, higher break 
down rates of NO due to increased oxygen delivery and direct oxygen sensing of endothelial cells might explain 
the increased resistance in HA with hyperoxia.
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Figure 2.  Oxygen delivery, vasculature resistance and patterns of vasoactive substance activation in experimental 
groups. Arterial PV group blue circles, n = 5 experiments, venous PV group red triangles, n = 5 experiments. (a,b) 
Representative experiment data of the HA and PV resistance from Group 0 without Nitroprussiat application. The 
increased HA resistance resulted in a decreased flow between perfusion day 1 and 3. From perfusion day 4, HA 
resistance decreased and was accompanied with increased PV resistance and absence of bile flow. (c) Oxygen delivery 
rate in the PV was higher with arterial PV compared to venous PV. (d,e) Oxygen saturation in the vena cava was higher 
in arterial PV group compared with venous PV group with no difference in oxygen uptake rate between groups during 
perfusion. (f) Resistance in arterial PV and venous PV groups controlled with Nitropurssiat. (g–l) Vasoactive substance 
release at mRNA and protein level without significant difference among experimental groups; (g) Endothelin-1 at 
mRNA level, (h) Endothelin-1 at protein level in tissue, (i) endothelial NO synthase (eNOS) and (j) inducible NO 
synthase (iNOS) at mRNA level, (k) NO level in perfusate, (l) heme oxygenase 1 at mRNA level. Superoxide dismutase 
(SOD) at mRNA (m) and protein (n) levels. P value * < 0.05, ** < 0.01, *** < 0.001. ns not significant.
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HA resistance regulation in vivo is complex, including extrinsic factors, such as neuro-humoral stimulation, 
which are missing in the ex vivo  setting7. Thus, tight control over HA hemodynamics is required during machine 
perfusion. Our findings demonstrate that excessive oxygen delivery during ex vivo liver perfusion further com-
promises vasculature resistance regulation, which can be improved by physiologic oxygen delivery in the PV. The 
rationale behind non-physiologic arterial oxygen content in the PV at the start of our experimental campaign 
was based on existing perfusion protocols in the  literature8,9. However, the liver has two hepatofugal vessels with 
venous blood in the PV and arterialization of the PV blood supply results in excess oxygen. Note, the observed 
hepatic venous blood oxygen saturation reaching 90% in arterial PV can be considered  safe10,20,21.
To recapitulate the in vivo situation, we delivered venous blood in the PV as a next step in the perfusion 
protocol development. This resulted in the unexpected reduction in demand for vasodilator. Previous studies 
demonstrated that HA resistance increases in response to increased PV flow and vice versa. This phenomenon is 
coined in the literature as hepatic arterial buffer response (HABR)7,22. As this work shows, HA resistance changes 
Figure 3.  Injury markers and liver function in experimental groups. Arterial PV group blue circles, n = 5 
experiments, venous PV group red triangles, n = 5 experiments. (a–c) Injury marker release in perfusate shown 
for AST (a), cytochrome c (b) and 8-OHdG (c). (d,e) Representative staining showing integrity on H&E 
staining (g) and preserved glycogen stores in PAS staining (h) after one week of perfusion. (f) Representative 
immunohistochemistry staining for Caspase 3 showing absence of relevant apoptosis on perfusion day 7. 
(d) Macrophages were not activated in both groups as shown with TLR4 at mRNA level. (e) Endothelial 
cell activation at mRNA level expressed with ICAM-1. (i) similarly to ICAM-1, von Willebrand Factor 
immunohistochemistry staining showed absence of relevant endothelial cell activation. (j) Bile flow was 
constantly present in both experimental groups for one week. (k,l) Livers cleared lactate (k) and maintained 
albumin level (l) in perfusate. P value * < 0.05, ** < 0.01, *** < 0.001. ns not significant.
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also depending on oxygen content in the PV. It has been recognized that vascular endothelial cells regulate the 
vascular smooth muscle tone and can sense  oxygen23–25. Endothelial cells have several oxygen sensing mecha-
nisms, including heme oxygenase, oxygen-sensitive NADPH oxidases, and eNOS among  others25. Hyperoxic 
vasoconstriction was first reported at least 100 years ago and confirmed consistently in in vivo  studies15,18,24,26. The 
logical question that arises is how can hyperoxia in the PV reach the hepatic arteriole, which regulates blood flow 
in most organs. Although, the terminal branches of the hepatic arteriole and portal vein lie within an enclosed 
space of Mall, arterial and portal blood mix in sinusoids. The unique feature of the hepatic blood flow regulation 
is that sinusoidal endothelial cells together with hepatic stellate cells and vascular smooth muscle cells control 
the resistance in the hepatic vascular  bed27,28. Indeed, vasoactive substances injected into the PV have similar 
access and effect on hepatic vascular bed compared to intra-arterial  injection7,29.
Although our observation is consistent with the physiology, the mechanism behind these findings is still 
illusive with controversial results. Most studies about vascular resistance have explored the release of vasoactive 
substances ET-1 and  NO18,26,30. ET-1 is a vasoconstrictor with the most long-lasting effect ever  discovered16,23,31. 
Although ET-1 is a well-known vasoconstrictor, its production and release in vivo is still poorly  understood16,23. 
Some studies claimed that high oxygen levels stimulate ET-1 production in vivo16,23. However, we could not 
confirm this hypothesis in our ex vivo setting.
Another vasoactive signaling molecule, NO, is involved in numerous physiological functions including 
vasodilation with a short half-life. Similar to ET-1, NO production was not different between the two groups. 
However, the applied Nitroprussiat is an NO donor and was infused at an increased rate with presence of exces-
sive oxygen. The mechanism behind increased NO demand with excessive oxygen is possibly due to increased 
rates of metabolism; the steady-state NO level depends on its synthesis and metabolism and both are oxygen-
dependent  processes32. Although NO reacts with oxygen directly (autoxidation) at a very slow rate, the significant 
NO metabolism occurs through reactions with free  radicals32,33. Superoxide is the most notable free radical in 
this context. Superoxide is a reactive oxygen ion and formed as a natural byproduct of oxidative  metabolism33. 
Superoxide undergoes extremely rapid radical–radical reaction with unpaired electrons present in NO forming 
 nitrates30,33. Its level is dependent on oxygen  concentration30,33,34. Thus, we propose that increased NO break 
down rate in presence of excessive oxygen might underlie the increased need for NO donors by reacting with 
free  radicals30. Owing to the very rapid metabolism rate, the detection/measurement of radicals was not possible 
in our setting. The increased NO need in excessive oxygen content was also shown consistently in studies with 
animals and  tissues30.
Beyond increasing the HA resistance, excessive oxygen might have a negative effect in injured human liv-
ers, since they are more susceptible to hyperoxia as was proposed in a clinical liver transplant  setting11. A 
group from Birmingham transplanted 12 initially discarded human livers. Of those, 6 were perfused with over 
oxygenation, including also arterial blood in the PV, while 6 were perfused with near-physiologic oxygen sup-
ply and venous blood in the PV. Although these authors did not note the clear difference in liver performance 
between high and low oxygen supply groups during ex vivo machine perfusion, the difference became apparent 
after transplantation. In this study, post-perfusion syndrome including primary graft non-function was linked 
to excessive oxygen during liver perfusion. Such a complication was not observed, when livers were perfused 
at near-physiologic oxygen tensions in the HA and venous blood in the PV11. This is the only study available 
in a clinical setting comparing the effect of excessive oxygen during ex vivo perfusion. The reported safety and 
feasibility of providing physiologic venous blood delivery in the PV during ex vivo perfusion with an optimized 
HA resistance regulation compared to non-physiologic arterial blood in the PV could support the application 
of such a perfusion loop in human livers grafts.
In the current manuscript we created partial oxygenation in the PV by mixing the blood (arterial and venous) 
directly in the PV line (Fig. 1 b). However, there are also other  possibilities8. One option would be to use two 
oxygenators separately for HA and PV and then adjust gas flows individually for every  oxygenator35. Using two 
oxygenators was upfront not an option in this project since the additional oxygenator increases the foreign surface 
area of the perfusion loop and thus, increases hemolysis. The oxygenator has the largest foreign surface area of all 
the system components. It also increases the machine costs and complexity, as it would require separate gas flow 
controllers (N2,  O2,  CO2)  for every oxygenator. Another option was to add a bypass from the oxygenator to the 
blood reservoir, which we tested initially in three experiments. With this approach, we observed a higher blood 
flow rate through the oxygenator to meet the oxygen demand. Moreover, we also observed a generally  higher 
hemoylsis rate (data not shown). Nonetheless, putting the bypass line directly from the HA to the PV line reduced 
the required flow rate and was suitable to maintain the desired physiologic oxygen saturation in the vena cava.
In conclusion, this work demonstrates that non-physiologic arterial oxygen content in the PV causes over 
supply of oxygen with consequent higher HA resistance. Physiologic venous blood in the PV during ex vivo 
liver perfusion is preferred as it improves the resistance control in the HA. Although the mechanism behind 
increased HA resistance by over oxygenation is not entirely clear in our system, we propose direct oxygen sensing 
of sinusoidal endothelial cells and/or increased NO break down rate with hyperoxia as possible explanations.
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